Loading
A Chinese study of 3,200 people testing whether a DNA sequencing blood test can detect seven common cancers and tell them apart.
Cell-free DNA sequencing to screen for and tell apart seven common cancers (NCT06036563) is an observational study sponsored by Air Force Military Medical University, China with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Tang-Du Hospital, The First Affiliated Hospital of Guangzhou Medical University and others. It asks whether a model based on peripheral blood cell-free DNA sequencing can screen for and classify seven common cancers, especially at early stages.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 16 May 2024), with an estimated 3,200 participants, a start on 1 September 2023 and primary completion expected in August 2025.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/